Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

This study suggests that men under 40 who develop persistent sexual side effects and insomnia after using finasteride for alopecia may be at increased risk of suicide.

This study found that finasteride may improve pulmonary and hepatic immune responses in mice when administered after major trauma and hemorrhage.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

The researchers proposed that an epigenetic change in brain androgen receptors caused by finasteride could lead to post finasteride syndrome, while trazodone might reverse this effect by altering the epigenetic expression related to erection and libido.

Ethosomes improve finasteride delivery through skin for hair loss treatment.

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

This case report suggests that oral finasteride, used for benign prostatic hyperplasia, may be associated with intraoperative floppy-iris syndrome during cataract surgery.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

In this study, finasteride altered acute ethanol withdrawal severity differently in male and female mice, highlighting sex differences in sensitivity to changes in neurosteroid levels.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.

This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.

This study found that altering neonatal neurosteroid levels affected anxiety and aversive learning in adult rats, possibly through changes in hippocampal GABAergic functions.

This study found that repeated finasteride administration in male Wistar rats led to increased depression-like behavior, suggesting an animal model for investigating finasteride's neuropsychiatric effects is viable.

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

Finasteride helped treat a 28-year-old's facial skin condition.

Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.

Finasteride may cause side effects; more research needed.

In this study, the researchers reported that while both propylene glycol and sodium lauryl sulfate enhanced finasteride's skin deposition, ethanol was the only effective enhancer of finasteride's permeation through the skin.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This study developed finasteride-containing granules using a method that improved follicular targeting for androgenic alopecia and reported potential for easy industrial production.

This study found that male pattern hair loss worsened significantly after stopping finasteride, revealing a "rebound effect" where terminal hair transformed into miniaturized hair over 30 months off the drug.

This study found that finasteride treatment of male rats led to changes in their male offspring's testicular gene expression, potentially affecting sperm function in response to odorant-like signals.

In this study, the release rate of Finasteride from Eudragit matrix tablets was found to be significantly influenced by the drug/Eudragit ratio and polymer viscosity, with formulation F9 being the most effective.